|
31/03/2025
|
10:30
|
Extraordinary General Meeting – Poll Results
|
RNS
|
|
21/03/2025
|
10:00
|
NMPA Conditional Approval for TAZVERIK®
|
RNS
|
|
20/03/2025
|
09:30
|
Retirement of Independent Non-executive Directors
|
RNS
|
|
20/03/2025
|
07:00
|
HUTCHMED Highlights Savolitinib SAVANNAH Phase II
|
RNS
|
|
19/03/2025
|
13:45
|
Publication of Form 20-F
|
RNS
|
|
19/03/2025
|
11:00
|
2024 Final Results and Business Updates
|
RNS
|
|
19/03/2025
|
07:00
|
Phase II/III Study of Fruquintinib and Sintilimab
|
RNS
|
|
14/03/2025
|
09:30
|
Adoption of the 2025 Long Term Incentive Plan
|
RNS
|
|
14/03/2025
|
09:30
|
Vesting of awards under Long Term Incentive Plan
|
RNS
|
|
13/03/2025
|
09:30
|
Notice of Extraordinary General Meeting
|
RNS
|
|
06/03/2025
|
10:00
|
Completed Enrollment of Phase II Study
|
RNS
|
|
05/03/2025
|
10:00
|
Directorate Change
|
RNS
|
|
03/03/2025
|
07:00
|
Overseas Regulatory Announcement
|
RNS
|
|
28/02/2025
|
15:00
|
Overseas Regulatory Announcement
|
RNS
|
|
19/02/2025
|
08:30
|
Notice of Results
|
RNS
|
|
28/01/2025
|
09:00
|
Overseas Regulatory Announcement
|
RNS
|
|
14/01/2025
|
07:00
|
Full Approval for ORPATHYS in China
|
RNS
|
|
02/01/2025
|
07:00
|
Overseas Regulatory Announcement
|
RNS
|
|
02/01/2025
|
07:00
|
US$608m Divestment of Non-Core Joint Venture
|
RNS
|
|
31/12/2024
|
08:30
|
Appointment of Joint Corporate Broker
|
RNS
|
|
30/12/2024
|
08:30
|
Blocklisting Six Monthly Return
|
RNS
|
|
13/12/2024
|
07:00
|
HUTCHMED to Receive Milestone Payment from Takeda
|
RNS
|
|
03/12/2024
|
10:00
|
HUTCHMED and Innovent Announce ELUNATE Approval
|
RNS
|
|
29/11/2024
|
08:30
|
Total Voting Rights
|
RNS
|
|
20/11/2024
|
09:30
|
Appointment of Independent Non-executive Director
|
RNS
|
|
31/10/2024
|
08:30
|
Total Voting Rights
|
RNS
|
|
21/10/2024
|
09:30
|
Vesting of awards under the LTIP
|
RNS
|
|
16/10/2024
|
07:00
|
SAVANNAH: clinically meaningful response rate
|
RNS
|
|
24/09/2024
|
08:00
|
Japan Approval for FRUZAQLA
|
RNS
|
|
30/08/2024
|
09:30
|
Total Voting Rights
|
RNS
|
|
30/08/2024
|
07:00
|
Update on Fruquintinib for Gastric Cancer in China
|
RNS
|
|
22/08/2024
|
09:30
|
Standard form for notification of major holdings
|
RNS
|
|
06/08/2024
|
10:00
|
LTIP and Share Option Scheme
|
RNS
|
|
31/07/2024
|
12:00
|
2024 Interim Results and Business Updates
|
RNS
|
|
28/06/2024
|
09:30
|
Blocklisting Six Monthly Return
|
RNS
|
|
28/06/2024
|
09:30
|
Total Voting Rights
|
RNS
|
|
26/06/2024
|
09:30
|
HUTCHMED to Announce 2024 HY Financial Results
|
RNS
|
|
24/06/2024
|
07:00
|
European Commission Approval for FRUZAQLA
|
RNS
|
|
31/05/2024
|
09:30
|
Total Voting Rights
|
RNS
|
|
17/05/2024
|
15:00
|
Retirement of Chairman and new Chairman appointed
|
RNS
|
|
10/05/2024
|
13:00
|
Result of AGM
|
RNS
|
|
08/05/2024
|
09:30
|
Directorate Change
|
RNS
|
|
26/04/2024
|
13:30
|
Positive CHMP Opinion for Fruquintinib
|
RNS
|
|
22/04/2024
|
09:30
|
Vesting of Awards Under the LTIP
|
RNS
|
|
08/04/2024
|
09:30
|
2023 Annual Report and Notice of AGM
|
RNS
|
|
14/03/2024
|
09:00
|
LTIP and Share Option Scheme
|
RNS
|
|
05/03/2024
|
08:30
|
Vesting of awards under the LTIP
|
RNS
|
|
28/02/2024
|
11:30
|
2023 Full Year Results and Business Updates
|
RNS
|
|
01/02/2024
|
08:30
|
HUTCHMED to Announce 2023 Final Results
|
RNS
|
|
29/12/2023
|
08:30
|
Total Voting Rights
|
RNS
|